Upload
ne3lsnetwork
View
301
Download
0
Embed Size (px)
DESCRIPTION
Parallel session 4
Citation preview
From Nanomedicine to NanohealthConceptualizing the biomedical model proposed by the
nanotech revolution
Mathieu Noury (PhD candidate)Université de MontréalUniversité de Paris – Ouest
Email : [email protected]
Summary
Nanomedicine and nanohealth. What is the difference?
A transversal medicine
An enhancement medicine
A global medicine
Conclusion
Nanomedicine and Nanohealth
‘‘The aim of nanomedicine maybe broadly defined as the comprehensive monitoring, repair, and improvement of all human biological systems, working from molecular level using engineered devices and nanostructures to achieve medical benefit”
European Science Foundation. (February 2005). ESF Scientific Forward Look on Nanomedicine, Strasbourg: ESF, p. 2.
Roco, M., Mirkin, C., & Hersam, M. (2010). Nanotechnology Research Directions for Societal Needs in 2020. US: Springer, p. 272.
Nanomedicine and Nanohealth
While nanomedicine is a general term referring to the various medical applications of nanotechnology, nanohealth is to be seen as a sociological tool aiming to grasp, at the same time, the specificity of the biomedical model proposed by the project of a nanomedicine and its social and cultural implications.
Nanomedicine and Nanohealth
1. A transversal model
1. A transversal model Predictive Medicine
‘‘In nanodiagnostic, the ultimate goal is to identify disease at the earliest stage possible, ideally at the level of a single cell’’
European Technology Platform on Nanomedicine. (September 2005). Vision Paper and Basis for a Strategic Research Agenda for Nanomedicine. Luxembourg: ETPN & European Commission, p. 6.
1. A transversal modelPersonalized Medicine
‘‘Nanotechnology enables further refinement of diagnostic techniques, leading to high throughput screening (to test one sample for numerous diseases, or screen large numbers of samples for one disease) and ultimately point-of-care diagnostics. These technological advancements pave the way towards major changes in the way drugs can be prescribed in future, by enabling the goal of personalized medicine that is tailored to individual needs’’.
European Technology Platform on Nanomedicine. (September 2005). Vision Paper and Basis for a Strategic Research Agenda for Nanomedicine. Luxembourg: ETPN & European Commission, p. 15.
1. A transversal modelRegenerative Medicine
‘‘Regenerative Medicine addresses the repair, replacement or regeneration of damaged tissues or organs via a combination of technological approaches. They can be divided into two sub-areas: smart biomaterials and advanced cell therapy. Ultimately, it is envisaged as being able to cure specific diseases or repairing damaged tissues, such as cartilage, bone, teeth, muscle, or nerves’’.
ETPN. (2009). Roadmaps in nanomedicine: towards 2020. Luxembourg: ETPN & European Comission, p. 31.
1. A transversal modelRegenerative Medicine
‘‘The body of the tissue engineering model does not simply spontaneously heal, but requires an elaborate apparatus for properly enframing the regenerative potential of cells and tissues’’.
Thacker, E. (2005). The Global Genome. Biotechnology, Politics, and Culture. Cambridge: MIT Press, p. 261.
2. An enhancement medicine
‘‘contemporary medical technologies do not seek merely to cure diseases once they have manifested themselves, but to control the vital processes of the body and mind. They are […] technologies of optimization’’.
Rose, N. (2007) The Politics of Life Itself. Biomedicine, Power, and Subjectivity in the Twenty-First Century, Princeton: Princeton University Press, p. 16.
2. An enhancement medicine
“regenerative medicine and nanomedicine have the potential to improve the health of Canadians and change the way our health care system protects, maintains and restores health”.
“[Nanomedicine] focuses on strategies that promote health and prevent disease. Its ultimate goal is to develop innovative and socially validated treatment approaches that will improve the quality of life of individuals and populations”. Canadian Institutes of Health Research. (2006). Regenerative medicine & Nanomedicine: Investing today in the promise of tomorrow, Ottawa: CIHR, p. 6-7.
2. An enhancement medicine
‘‘The medicalization and disease-mongering phenomenon increases and moves toward the transhumanization of medicalization, where enhancing, improving and modifying the human body beyond its species-typical boundaries is part of the concept of being healthy’’.
Wolbring, G. (2005). The triangle of enhancement medicine, disabled people, and the concept of health : a new challenge for HTA, health research, and health policy. Edmonton: Alberta Heritage Foundation for Medical Research, p. 3.
3. A global medicine
Major governmental investments in nanotechnology (including
nanomedicine)
3. A global medicine
Nanomedicine indicates the centrality of what many people has starting to call an “economic-industrial-technological-scientific-complex” of technoscience, which has replaced the declining “military-industrial complex.”
3. A global medicine
“The OECD Project supposes the bioeconomy to be the aggregate set of economic operations in a society that use the latent value incumbent in biological products and processes to capture new growth and welfare benefits for citizens and nations. […] The bioeconomy is made possible by the recent and continuing surge in the scientific knowledge and technical competences that can be directed to harness biological processes for practical applications.
[…] Unsurprisingly therefore, strategic interest is growing in the biosciences in both OECD and non-OECD countries. Indeed, the bioeconomy is growing faster in China, India and Singapore than in many OECD countries and the lead position occupied by OECD countries in most fields is being challenge”.
OECD. (2006). The Bioeconomy to 2030: Designing a Policy Agenda. Paris: OECD, p. 1-2
3. A global medicine
R.: Canada has an opportunity to take a leader role in regenerative medicine. If we don’t do it, someone else will. If someone else does it, we will still pay for it and we won’t take as much of the economic benefits. So you cannot stop it. No one cares of Canada, no ones worldwide cares of Canada funds it or not. At the end, everyone would want its benefit. So if we have an opportunity to become a significant player, and something has going to happen anyways, we should take it. M.: Do you think there is a worldwide pressure to develop this… R.: …it’s not so much a pressure, it’s a race.
Conclusion